Cambium Bio Limited has released a press release.
Cambium Bio: Half Year Report and Accounts
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Cambium Bio
- Quarterly Activities/Appendix 4C Cash Flow Report
- Cambium Bio Secures A$2.4 Million Strategic Investment
- Cambium Bio Signs Strategic MoU with Benta SAS
- Cambium Bio Signs US$2.0M plus Licensing Deal
- FY25 Appendix 4E and Annual Report
Later from Cambium Bio
- FDA Confirms Single Pivotal Trial Pathway for Elate Ocular
- Cambium Bio Raises A$1.0 Million via Placement
- FY26 Appendix 4E and Annual Report
- Cambium Bio Secures A$10.85 Million Funding Package
- Cambium Bio Secures A$10.85 Million to Initiate Pivotal Phase 3 Trial of Elate Ocular®, a Potential First-in-Class Biologic for Dry Eye Disease
Follow Cambium Bio into a list and get an email when it puts out news.
Follow Cambium Bio